Your Article Summary
See Latest ArticlesA cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US
Current Medical Research and Opinion, 06/25/09
Charles MS et al. - Under a range of assumptions and study limitations around cohorts, clinical effects, and treatment patterns, this long-term analysis showed that pioglitazone plus metformin, when compared to rosiglitazone plus metformin, was a dominant treatment strategy within the US payer setting. Results were driven by the combination of modest differences in QALYs and modest savings in total complication costs over 35 years.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 12/02/09
Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus
Pharmacotherapy, 12/02/09
The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Pharmacotherapy, 12/02/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09
Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
PharmacoEconomics, 11/30/09